The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

被引：20
|
作者：
Heymach, J. [1 ]
Taube, J. [2 ]
Mitsudomi, T. [3 ]
Harpole, D. [4 ]
Aperghis, M. [5 ]
Trani, L. [5 ]
Powell, M. [6 ]
Dennis, P. [6 ]
Reck, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osakasayama, Japan
[4] Duke Univ, Dept Surg, Durham, NC USA
[5] Astrazeneca, Cambridge, England
[6] Astrazeneca, Gaithersburg, MD USA
[7] Airway Res Ctr North, Grosshansdorf, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Chemotherapy; durvalumab; NSCLC;
D O I：
10.1016/j.jtho.2019.08.1318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.18-02
引用
收藏
页码：S625 / S626
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant low-dose radiotherapy plus durvalumab and chemotherapy for potentially resectable stage III NSCLC: A phase Ib dose-escalation study
    Li, Juan
    Lu, Shun
    Tian, Yuke
    Jiang, Lan
    Li, Lu
    Xie, Shao-Hua
    Li, Qiang
    RADIOTHERAPY AND ONCOLOGY, 2024, 196
  • [22] Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Hong, M. H.
    Ahn, B.
    Kim, H. R.
    Lim, S. M.
    Lee, S.
    Park, S. Y.
    Lee, C. Y.
    Lee, J. G.
    Kim, D. J.
    Lee, S. H.
    Yoon, H. I.
    Lee, C. G.
    Cho, J.
    Shim, H. S.
    Kim, T.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S194 - S195
  • [23] Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
    Thanikachalam, Kannan
    Damarla, Vijay
    Seixas, Trevor
    Dobrosotskaya, Irina
    Wollner, Ira
    Kwon, David
    Winters, Kenneth
    Raoufi, Mohammad
    Li, Jia
    Siddiqui, Farzan
    Khan, Gazala
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (06): : 435 - 441
  • [24] DUART: A phase II study of durvalumab following radiotherapy in patients with unresectable, stage III NSCLC ineligible for chemotherapy
    Filippi, A. R.
    Dziadziuszko, R.
    Garcia Campelo, M. R.
    Paoli, J-B.
    Sawyer, W.
    Perez, I. E. Diaz
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S747 - S747
  • [25] Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches
    Tarhini, Ahmad A.
    Castellano, Ella
    Eljilany, Islam
    CANCER JOURNAL, 2024, 30 (02): : 54 - 70
  • [26] Neoadjuvant Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC: Interim Analysis of ALNEO-GOIRC-01-2020 Phase II Trial
    Leonetti, A.
    Boni, L.
    Gnetti, L.
    Cortinovis, D. L.
    Mazzoni, F.
    Pasello, G.
    Passiglia, F.
    Bearz, A.
    Pilotto, S.
    Gelsomino, F.
    Metro, G.
    Bertolini, F.
    Toschi, L.
    Parra, H. Soto
    Delmonte, A.
    Cecere, F. L.
    Ricciardi, S.
    Bria, E.
    Tognetto, M.
    Tiseo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S52 - S52
  • [27] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Hozaeel, Wael
    Pauligk, Claudia
    Homann, Nils
    Luley, Kim
    Kraus, Thomas Werner
    Trojan, Jorg
    Bechstein, Wolf O.
    Grimm, Kersten
    Heise, Bettina
    Schmiegel, Wolff
    Pink, Daniel
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
    Al-Batran, Salah-Eddin
    Reichart, Alexander
    Bankstahl, Ulli Simone
    Pauligk, Claudia
    Kraus, Thomas Werner
    Bechstein, Wolf Otto
    Trojan, Jorg
    Behrend, Matthias
    Potenberg, Jochem
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Alber, Karsten
    Siegler, Gabriele Margareta
    Hozaeel, Wael
    Goetze, Thorsten Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [29] A Response to the Letter to the Editor "Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?"
    Marinelli, Daniele
    Gallina, Filippo Tommaso
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (03) : e43 - e44
  • [30] A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non Small Cell Lung Cancer (NSCLC)
    Owen, Dwight
    Bunn, Paul, Jr.
    Johnson, Bruce
    Kwiatkowski, David
    Kris, Mark
    Wistuba, Ignacio
    Gandhi, Mayank
    Phan, See
    Shames, David
    Schulze, Katja
    Bernaards, Coen
    Aisner, Dara
    Chaft, Jamie
    Gainor, Justin
    Lee, Jay
    Minna, John
    Mino-Kenudson, Mari
    Garcia-Prieto, Celia
    Rusch, Valerie
    Sabichi, Anita
    Villaruz, Liza
    Wozniak, Antoinette
    Carbone, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1082 - S1082
12345